Scleroderma Induced by Pembrolizumab: A Case Series

Naiara S. Barbosa, David A. Wetter, Carilyn N. Wieland, Niraj K. Shenoy, Svetomir N. Markovic, Uma Thanarajasingam

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

Original languageEnglish (US)
Pages (from-to)1158-1163
Number of pages6
JournalMayo Clinic Proceedings
Volume92
Issue number7
DOIs
StatePublished - Jul 2017
Externally publishedYes

Fingerprint

Melanoma
Limited Scleroderma
Diffuse Scleroderma
Immune Tolerance
Autoimmune Diseases
Therapeutics
Survival
pembrolizumab
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Barbosa, N. S., Wetter, D. A., Wieland, C. N., Shenoy, N. K., Markovic, S. N., & Thanarajasingam, U. (2017). Scleroderma Induced by Pembrolizumab: A Case Series. Mayo Clinic Proceedings, 92(7), 1158-1163. https://doi.org/10.1016/j.mayocp.2017.03.016

Scleroderma Induced by Pembrolizumab : A Case Series. / Barbosa, Naiara S.; Wetter, David A.; Wieland, Carilyn N.; Shenoy, Niraj K.; Markovic, Svetomir N.; Thanarajasingam, Uma.

In: Mayo Clinic Proceedings, Vol. 92, No. 7, 07.2017, p. 1158-1163.

Research output: Contribution to journalArticle

Barbosa, NS, Wetter, DA, Wieland, CN, Shenoy, NK, Markovic, SN & Thanarajasingam, U 2017, 'Scleroderma Induced by Pembrolizumab: A Case Series', Mayo Clinic Proceedings, vol. 92, no. 7, pp. 1158-1163. https://doi.org/10.1016/j.mayocp.2017.03.016
Barbosa NS, Wetter DA, Wieland CN, Shenoy NK, Markovic SN, Thanarajasingam U. Scleroderma Induced by Pembrolizumab: A Case Series. Mayo Clinic Proceedings. 2017 Jul;92(7):1158-1163. https://doi.org/10.1016/j.mayocp.2017.03.016
Barbosa, Naiara S. ; Wetter, David A. ; Wieland, Carilyn N. ; Shenoy, Niraj K. ; Markovic, Svetomir N. ; Thanarajasingam, Uma. / Scleroderma Induced by Pembrolizumab : A Case Series. In: Mayo Clinic Proceedings. 2017 ; Vol. 92, No. 7. pp. 1158-1163.
@article{5dfb4fcbbcdc4ecf8cd090d54b7e5773,
title = "Scleroderma Induced by Pembrolizumab: A Case Series",
abstract = "Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.",
author = "Barbosa, {Naiara S.} and Wetter, {David A.} and Wieland, {Carilyn N.} and Shenoy, {Niraj K.} and Markovic, {Svetomir N.} and Uma Thanarajasingam",
year = "2017",
month = "7",
doi = "10.1016/j.mayocp.2017.03.016",
language = "English (US)",
volume = "92",
pages = "1158--1163",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Scleroderma Induced by Pembrolizumab

T2 - A Case Series

AU - Barbosa, Naiara S.

AU - Wetter, David A.

AU - Wieland, Carilyn N.

AU - Shenoy, Niraj K.

AU - Markovic, Svetomir N.

AU - Thanarajasingam, Uma

PY - 2017/7

Y1 - 2017/7

N2 - Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

AB - Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.

UR - http://www.scopus.com/inward/record.url?scp=85020182824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020182824&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2017.03.016

DO - 10.1016/j.mayocp.2017.03.016

M3 - Article

C2 - 28599746

AN - SCOPUS:85020182824

VL - 92

SP - 1158

EP - 1163

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -